OSTX OS Therapies Inc
Pharmaceutical Preparations · NYSE · SEC CIK 1795091 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-139.4%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-513.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets296.1%
Debt / equity—
Current ratio0.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-296.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $16.36M | $2.84M | $3.22M |
| SG&A expense | $12.34M | $3.97M | $1.13M |
| Operating income | -$28.71M | -$6.81M | -$4.34M |
| Interest expense | — | $2.05M | $3.45M |
| Net income | -$28.75M | -$8.88M | -$7.79M |
| EBITDA | -$28.34M | -$6.81M | -$4.34M |
| EPS (basic) | -0.98 | -1.28 | -1.46 |
| EPS (diluted) | -0.98 | -1.28 | -1.46 |
| Weighted avg. shares (diluted) | 29.25M | 6.95M | — |
| Banking | |||
| Deposits | — | $150,000 | — |
| Balance sheet | |||
| Cash & equivalents | $269,830 | $5.53M | $38,982 |
| Current assets | $332,912 | $5.53M | $790,032 |
| PP&E, net | $2,490 | $5,270 | $8,050 |
| Intangibles | $6.50M | — | $8,050 |
| Total assets | $6.84M | $5.54M | $798,082 |
| Current liabilities | $11.76M | $4.63M | $24.71M |
| Total liabilities | $11.86M | $4.73M | $24.81M |
| Shareholders' equity | -$6.10M | -$3.27M | -$24.02M |
| Shares outstanding | 37.11M | 20.87M | 5.34M |
| Cash flow statement | |||
| Operating cash flow | -$14.24M | -$7.28M | -$3.01M |
| Capital expenditure | $466,423 | — | — |
| Free cash flow | -$14.70M | — | — |
| Investing cash flow | -$466,423 | — | $1,145 |
| Financing cash flow | $9.44M | $12.78M | $2.87M |
| Depreciation & amortization | $363,085 | $2,780 | $4,220 |
| Stock-based compensation | $4.27M | $268,300 | $0 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.